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Summary.-The tumour specific transplantation antigen (TSTA) from a chemically
induced rat sarcoma has been isolated as an electrophoretically homogeneous
soluble material by affinity chromatography using a Sepharose bound antibody
raised to the tumour in syngeneic rats. The TSTA is specific for the particular
tumour used (the MC-1 sarcoma) and does not cross-react with material extracted
from other rat sarcomata. In addition, a material with different physicochemical
properties which cross-reacted with different sarcomata was also eluted from the
antibody column and this may be the previously identified onco-embryonic antigen
(OEAl) which is immunogenic in the syngeneic host.
The purified TSTA labelled with 125I was used in a radioimmunoassay which
detected soluble TSTA in rats bearing a MC-1 sarcoma. The assay shows that
tumour transplantation is associated with a persisting release of soluble antigen
into the circulation. This antigenic burden is present continuously and renewed as
long as the tumour mass exists.
THE EXISTENCE of individually unique
tumour specific transplantation antigens
(TSTA) has been demonstrated in the
membranes of chemically induced sarco-
mata of experimental animals by in vivo
transplantation methods and by in vitro
tests (Old and Boyse, 1964; Baldwin and
Barker, 1967; Hellstrom and Hellstr6m,
1969). Recently, TSTA solubilization has
been achieved either by limited papain
digestion or by hypertonic salt extraction
and the antigenic components isolated
from any one tumour by various pro-
cedures are, in general, heterogeneous as
measured by polyacrylamide gel electro-
phoresis (Holmes, Kahan and Morton,
1970; Meltzer et al., 1971; Baldwin and
Glaves, 1972; Thomson and Alexander,
1973a). We describe here the direct
purification of such solubilized TSTA
obtained from isolated tumour cell mem-
branes by affinity chromatography, using
syngeneic antiserum directed against the
tumour. Antibodies directed to the TSTA
of transplantable sarcomata are found
in the sera of syngeneic rats following
surgical excision of the tumour and
hyperimmunization with tumour cells
(Thomson, Steel and Alexander, 1973b).
Such sera also contain an antibody which
reacts against another tumour associated
membrane antigen which, unlike the
TSTA, is not unique to individual sarco-
mata but is found in most rat sarcomata
and also in the tissues from early embryos.
For this reason this material has been
called " oncoembryonic antigen " (OEA1)
(Thomson and Alexander, 1973a). In
addition, the sera from rats frequently
carry autoantibodies to normal tissue
components (Weir and Elson, 1969), but
these can be removed by absorption
with homogenates from normal rat cells.
Contamination with OEA1 or normal
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tissue antigens ofthe material eluted from
syngeneic antisera to the MC-1 rat
sarcoma was avoided by taking suitable
precautions. A particular advantage of
the method described here is that the
Sepharose linked tumour immune y-
globulin employed for the isolation of the
TSTA is also used for the radioimmuno-
assay of the TSTA, in which the soluble
TSTA isolated by affinity chromato-
graphy and then labelled with 1251 is used
as antigen.
MATERIALS AND METHODS
Tumours used.-A 20-methylcholanthrene
induced sarcoma carried in syngeneic male
hooded rats and designated MC-1 was used
in its early transplant generations. The
MC-1 tumour is highly immunogenic and
does not cross-react with other chemically
induced sarcomata when assessed by trans-
plantation tests (Thomson and Alexander,
1973a; Thomson et al., 1973b). To check
the specificity of the TSTA isolates from the
MC-1 tumour another 20-methylcholanthrene
induced syngeneic hooded rat sarcoma desig-
nated MC-3 was used.
Anti-serum.-Immune serum to the MC-1
tumour was raised by inoculating syngeneic
male rats with tumour cells intramuscularly
and surgically excising the resulting tumour
2 weeks later. These rats then received
repeated injections at multiple sites of
irradiated tumour cells (15,000 rad) over a
period of 3 months. y-globulins from im-
mune sera were partially purified by 40%
ammonium sulphate precipitation. Similar
antisera were raised to 2 unrelated trans-
planted methylcholanthrene induced sarco-
mata which were also syngeneic in male
hooded rats and these tumours were desig-
nated MC-9 and MG-Il.
Removal of autoimmune antibodies in
syngeneic tumour immune serum by absorp-
tion.-Soluble proteins from the 3 mol/l KCG
extraction of a pool of normal rat organs
were cross-linked with glutaraldehyde as
previously described (Thomson et al., 1973b;
Avrameas and Ternynck, 1969). The solid
immunoabsorbent obtained was employed
in a batch-wise technique to absorb auto-
antibodies from the syngeneic y-globulins
of MC-1 tumour immune serum.
Solubilization and labelling of antigen.-
Water soluble antigens were prepared from
the MC-1 tumour and to serve as a control
from the MC-3 tumour either by digesting
crude membrane material with papain or
extracting solid tumour after gentle homo-
genization with 3 mol/l KCG. Both these
procedures have been described previously
(Thomson and Alexander, 1973a). Extracts
were labelled with 125I by the method of
Greenwood, Hunter and Glover (1963) using
chloramine T.
Gel chromatography.-The solubilized ex-
tract of tumour was applied to a Biogel A
0 5 mol/l (Biorad Laboratories Ltd.) column
(4 x 55 cm) and eluted at 4°C with buffer
consisting of 0 3 mol/l glycine, 0-1 mol/l
Tris, 0-2 mol/l NaCl, 1 mmol/l EDTA, pH
8-0 by upward flow. Fractions eluted from
the column were pooled into 5 separate
fractions, concentrated against Aquacide 11
(Calbiochem) to approximately 8 ml and
dialysed against PBS (phosphate buffered
saline, pH 7.3).
Polyacrylamide gel electrophoresis (PAGE).
-A slightly modified version of the original
procedure described by Davis (1964) was
employed using 5 mm x 70 mm tubes for
the gels which were made up with 7.5% (w/v)
acrylamide and 0-2% methylene-bis-acryl-
amide in a 0 4 mol/l Tris-HCl buffer at pH
8-9 and cross-linked with ammonium per-
sulphate. Samples of 20 ,lI of 125I labelled
antigen (0-15 mol/l NaCl, 0.01 mol/l Tris-
glycine, pH 7.6) were preincubated with
30 pl of y-globulin or buffer alone and then
mixed with 20 ,ul of 20% sucrose and bromo-
phenol blue. These solutions were layered
carefully on the gel surfaces and electro-
phoresis was carried out at 2°C using a
pulsed constant power supply (Ortec). Gels
were sectioned at 1i5 mm intervals.
Separation by affinity chromatography with
Sepharose coupled antibody.-The y-globulin
fraction from syngeneic MC-1 immune serum
isolated by ammonium sulphate precipitation
was linked covalently to cyanogen bromide
activated Sepharose 4B in a 0-2 mol/l pH
6-5, citrate buffer by the method of Cuatre-
casas (1970). Tumour extracts or fractions
obtained after gel chromatography in 0-15
mol/l NaCl and 0-01 mol/l Tris-HCl buffer
at pH 7X6 were applied to a columnn containing
30 ml of the Sepharose linked y-globulin.
Application was at 20°C and flow was
occluded for one hour, after which the
column was washed with 500 ml of the
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same buffer. Subsequently 2-5 mol/l MgC]2
in 0 01 mol/l Tris-HCl pH 7-6 at 4°C was
applied to the column and a peak of protein
was eluted. The eluted protein was dialysed
against 200 volumes of 0d15 mol/l NaCl,
0-01 mol/l Tris-HCl buffer, pH 7-6, and
concentrated to 1 ml by ultrafiltration
(Amicon).
Radioimmunoassay for TSTA.-A solid
phase radioimmunoassay was developed using
the coupled MC-1 immune y-globulin and
isolated 1251 labelled TSTA. The antibody-
Sepharose conjugate was titrated by incubat-
ing it in serial dilutions with 100 yd of 1251
labelled MC-1 TSTA (approximately 10,000
ct/min) in 0-15 mol/l NaCi, 0 01 mol/l Tris-
HCl buffer, pH 7 6, with 0-5% albumin at
4°C for 24 hours. At the end of the period,
antibody bound [1251]TSTA was separated
from free [1251]TSTA by centrifugation at
2000 g for 15 min at 4°C. The supernatant
was discarded and the precipitate was
washed in 10 ml of the same buffer 3 times.
The radioactivity of the precipitate was
counted in an automatic gamma spectro-
meter. The antibody-Sepharose conjugate
in an appropriate volume (100 [tl) of 25%
solution (v/v) bound 300o of the added
[1251]TSTA. This quantity of antibody con-
jugate was used for the subsequent detection
of TSTA by inhibition of uptake of [1251]
TSTA. Standard inhibition curves wNere
obtained by incubating serial volumes of
standard unlabelled MC-1 TSTA isolated by
affinity chromatography with anti MC-1
TSTA Sepharose conjugate. 100 yul of
[1251]MC-l TSTA was then added to each
tube and incubated for 24 hours at 4°C.
Antibody bound and free [125T]TSTA were
separated.
Serum w%as obtained from normal, MC-1
and unrelated tumour bearers and stored at
-20°C. All serum and lymph samples were
fractionated with pH 3-1 glycine-HCl on
an Amicon XM-100 membrane as previously
described (Thomson et al., 1973b) and the
molecular weight fraction less than 100,000
daltons, the " antigen fraction ", was tested
for TSTA activity. All samples were assayed
in duplicate and frequently the assay
was repeated. 0-3 ml of the " antigen
fraction" derived from 2 ml of a serum
or 5 ml of a lymph sample were assayed.
Thoracic duct cannulation, collection and
preparation of lymph were as previously des-
cribed (Thomson, Eccles andAlexander 1973c).
RESULTS
Preliminary purification by gel exclusion
chromatogr-aphy
The material solubilized by either
papain treatment or KCI extraction of
membranes from the MC-1 sarcoma was
chromatographed on Biogel AO5 m. The
eluate was pooled into 5 fractions which
covered different molecular size ranges.
F. 1 contains the higher molecular weight
substances which are excluded by the gel
and the other 4 fractions are the included
materials of relatively lower molecular
weight, fraction F5 containing substances
of the lowest molecular weight range
studied. The eluate patterns have been
published previously (Thomson and Alex-
ander, 1973a). These fractions were as-
sayed for their ability to block specifically
the binding of antibody in MC-1 immune
serum to the tumour specific cell surface
antigens on viable MC-1 sarcoma cells.
The presence of TSTA in any fraction
was indicated by a reduction in the
fluorescence index (as defined in Thomson
and Alexander, 1973a) of absorbed serum
compared with serum diluted with an
equivalent volume of phosphate buffered
saline or normal tissue antigens solubilized
by the KCI method. The data presented
in the Table show that the MC-1 tumour
specific antigenic determinant could be
solubilized and partially purified by gel
chromatography. The relative elution
volume (Ve/Vo) of the most active
fraction was 2*4.
Further purification by affinity chromato-
graphy using Sepharose-conjugated y-glo-
bulin from syngeneic antiserum to the
MC-I tumour
Papain and KCI extracts from the
MC-I and MC-3 sarcomata without further
purification, as well as the F5 fraction
from the gel chromatography of the MC-1
tumour extracts, were applied to a
column of Sepharose coupled y-globulin
from syngeneic MC-1 immune serum and
eluted with magnesium chloride. The
Table shows that the eluate obtained,
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TABLE.-TSTA Activity in Extracts
from Tumours
Extracts added to antibody
3 mol/l KCI extract from normal
rat tissues
3 mol/1 KCI extract from MC-1
sarcoma
3 mol/l KCI extract from MC-3
sarcoma
Gel chromatography fractions of
papain solubilized extract of
MC-1 sarcoma:
Fraction F1
Fraction F2
Fraction F3
Fraction F4
Fraction F5
Eluate off Sepharose-coupled anti
MC-1 y-globulin from:
Papain extract ofMC- 1 sarcoma
3 mol/l KCI extract of MC- 1
sarcoma
Fraction F5 from papain ex-
tract of MC-1 sarcoma
3 mol/l KCI extract of MC-3
sarcoma
% reduction
in fluorescence
index
5
40
20
15
25
15
30
70
60
35
55
10
Activity measured by capacity of extract to
inhibit the binding of syngeneic anti MC-1 y-globulin
to the membranes of living MC-1 sarcoma cells.
after applying the 3 extracts from the
MC-1 tumour but not that from the
MC-3 tumour, inhibited the capacity of
syngeneic antiserum to the MC-1 tumour
to bind to the membrane of MC-I cells.
These findings indicate that the TSTA
present in the different extracts bound to
the anti-MC-I y-globulin coupled to Sepha-
rose and that the TSTA could be re-
covered by elution with chaotropic agents.
Materials eluted from the columns
of Sepharose linked syngeneic antibody
to the MC-1 tumour were labelled with
1251 and analysed by polyacrylamide
gel electrophoresis (PAGE). Fig. la and
lb show that the material originating
respectively from a KCO extract of the
MC-1 and the MC-3 sarcomata have
several electrophoretic components. When
the 1251 labelled eluate derived from the
MC-1 tumour was mixed with increasing
proportions of y-globulin from MC-1
immune serum before being analysed by
PAGE, the principal peaks progressively
reduced and radioactivity increased in
the zone of low mobility. In contrast,
y-globulin from the serum of normal
rats did not affect the major peaks
appearing with a relative mobility of
0.36 and 0*68. The material originating
from the MC-3 tumour and eluted off
the solid phase coupled anti-y-globulin
to the MC-I tumour had a principal
peak at 0-68 but this material (see Table)
does not contain TSTA activity. These
experiments suggest that the material
which moves on PAGE with a relative
mobility of 0-68 is not the TSTA.
The eluates obtained from the coupled
y-globulin after applying tumour extracts
may contain not only tumour specific
substances which are antigenic in the
syngeneic host (i.e. TSTA or OEAI)
but also normal cell constituents, to
which the rat had developed autoanti-
bodies (Weir and Elson, 1969). To elimi-
nate the presence of the latter, the y-
globulin isolated from the syngeneic
antiserum to the MC-1 tumour was
absorbed by normal rat tissue before
being used for affinity chromatography.
Fig. lc and Id show the patterns on
PAGE of eluates from the absorbed
y-globulin using as a starting material
fraction 5 of a MC-1 papain-solubilized
extract which contains the TSTA activity.
Fig. lc shows that a sharply defined
peak was obtained with a relative mobility
of 0.36. Incubation of the 125I labelled
proteins with normal rat y-globulin did
not alter the position of the peak. To
demonstrate that this peak was related
to the TSTA which is unique to the
MC-1 sarcoma, and not shared by other
sarcomata syngeneic to the same hooded
strain of rats, the eluate from the MC-1
tumour (F5 fraction) was incubated with
y-globulin either from syngeneic anti-
serum to the MC-1 tumour or a mixture
from syngeneic antisera to 2 other hooded
rat sarcomata. Fig. Id shows that after
addition of the MC-1 serum, material
moved much more slowly and the original
peak at 0-36 relative mobility was totally
obliterated. On the other hand, the
y-globulin to the other tumours had no
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FIG. 1.-Polyacrylamide gel electrophoresis patterns of radioiodinated 125I proteins from tumour
extracts after purification by affinity chromatography on Sepharose-linked y-globulin from syn-
geneic antisera to the MC-1 sarcoma. The abscissa records the mobility relative to bromophenol
blue which was used as the tracking dye.
Eluates off unabsorbed anti-MC-i y-globulin from: (a) material obtained by extraction of
MC-1 tumour by 3 mol/I KCI 0 diluted with buffer, 0 anti MC-1 serum added; (b) material
obtained by extraction ofMC-3.
Eluates off anti-MC-i y-globulin after absorption by normal rat tissues from: (c) F5 fraction
ofMC-1 tumour; (d) F5 fraction ofMC-1 tumour. 0 syngeneic antiserum to MC-1 added. * syn-
geneic antisera to MC-9 and MC-11 tumour added; (e) F4 fraction of MC-1 tumour.
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such effect. These experiments demon-
strate that an electrophoretically homo-
geneous material with TSTA properties
can be isolated in a two-stage process,
involving firstly gel chromatography of a
KCI or papain extract from the tumour
and secondly elution of the F5 gel chro-
matography fraction from suitably ab-
sorbed syngeneic antibodies bound to
Sepharose.
When the F4 gel chromatography
fraction of the MC-1 tumour, which does
not contain TSTA activity, was separated
by affinity chromatography with anti-
MC-1 y-globulin, an eluate giving a peak
on PAGE with a relative mobility of
0*68 was obtained (see Fig. le). A
similar single peak was obtained from
eluates of a KCI extract of the MC-3
tumour. These experiments suggest that
the material isolated in this way and
having a relative mobility of 0 68 is
OEAI. However, the possibility that it
is yet another cross-reacting tumour
associated substance which is antigenic in
the syngeneic host has not been excluded.
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Radioimmunoassay for TSTA
The purified TSTA labelled with 1251
was used with Sepharose coupled anti-
MC-1 tumour immune y-globulin in a
solid phase radioimmunoassay. A maxi-
mum specific binding of 60% of the
[1251]TSTA was obtained in the presence
of anti-MC-1 TSTA antibody excess.
One per cent (1%) of the radiolabelled
TSTA bound nonspecifically to Sepharose.
A dilution of antiserum, which provided
conditions of antigen excess and which
specifically bound 300o ofthe added radio-
label, was used to obtain the standard
inhibition curve. This quantity of the
antibody-Sepharose conjugate was ob-
tained in a volume of 100 pl of 25%
solution (v/v).
A typical standard inhibition curve
is shown in Fig. 2. The curve demon-
strates a linearity. A standard unlabelled
TSTA isolated by affinity chromatography
showed increasing inhibition with increas-
ing amounts (volume) of added antigen.
Since insufficient material was available,
the weight ofTSTA present in the samples
Serum Volume (ul)
I I I
50 100 200 40C)
nIA
j I I I _ I --I
25 50 100 200 400 800
MC-1 TSTA (Volume,Al)
FIG. 2. Standard inhibition curve was produced using increasing volumes of unlabelled MC-1
TSTA (-). The other curves show the inhibition given by serial dlilutions of serum from MC-1
tumour bearers (0), MC-3 soluble tumour specific antigen (0) and serum from unrelated MC-3
tumour bearer (A).
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was not determined. Consequently, the
assay for the soluble TSTA in serum has
to be expressed in arbitrary units of %
inhibition.
Affinity chromatography isolates of a
3 mol/l KCI extract of an unrelated
MC-3 tumour gave no significant inhibi-
tion (Fig. 2). Normal, MC-1 and un-
related sera from tumour bearers were
fractionated with pH 3-1 glycine-HCl on
an Amicon XM-100 membrane and the
fraction less than 100,000 daltons, "anti-
gen fraction ", was assayed for TSTA
activity. Sera from normal animals or
animals bearing unrelated tumours gave
minimal inhibition of binding. Sera from
MC-1 tumour bearers gave significant
inhibition of binding and an inhibition
curve was linear and parallel to the
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standard curve (Fig. 2). This is strong
evidence that the inhibitory material is
MC-1 TSTA of less than 100,000 daltons.
On occasion, serum from unrelated
tumour bearers, but never normal serum,
gave cross-reacting inhibition of binding
in the radioimmunoassay. This occurred
when the labelled MC-1 TSTA ernployed
in the assay was isolated from Sepharose
coupled with unabsorbed MC-1 tumour
immune y-globulin and the coupled anti-
body in the radioimmunoassay was like-
wise unabsorbed.
Concentrations of MIC-1 TSTA in serum
and lymph of rats
Fig. 3 shows the changes which occur
in serum levels of TSTA during the
course of tumour growth (following
...'
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FIG. 3. Radioimmunoassay for MC-I TSTA in the serum of rats following inoculation of 2 x 106
MC-1 sarcoma cells intramuscularly in the right leg. Each point represents serum from one
individual rat. Normal rats ( #), (500 rad) W.B. irradiated rats (O).
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inoculation of 2 x 106 MC-1 sarcoma
cells) and after complete surgical removal
of the tumour in normal and immuno-
suppressed animals. The relatively high
amounts of TSTA found immediately
after i.m. inoculation of 2 x 106 MC-1
cells in normal animals is not unexpected
since Julian Proctor (unpublished obser-
vations) has found that following i.m.
inoculation of radiolabelled sarcoma cells
9000 of these are broken down within
24 hours and the radioactive material
appears in the urine. The TSTA of
these autolysed cells enters the circulation
and lymph.
In previous experiments (Thomson et
al., 1973b) when studying the blood level
of soluble TSTA in rats with the MC-1
sarcoma, it was shown that the serum
oftumour bearers contained excess tumour
antigen and immune complexes. In an
attempt to obtain a higher yield of free
tumour antigen in the serum these tumours
were grown in rats given 500 rad of total
body x-irradiation. A totally unexpected
finding was that the sera from these
animals gave evidence of circulating
TSTA only at 21 days. In the present
study this experiment was repeated.
Rats were given 500 rad of total body
x-irradiation followed by MC-1 tumour
implantation. Serum from separate indi-
vidual animals was drawn over 20 days
and examined by radioimmunoassay for
MC-1 TSTA. The values obtained are
shown in Fig. 3. Although the tumours
were smaller and firmer when grown in
immunosuppressed animals compared with
normal animals, this does not explain
the absence of detectable circulating
MC-1 TSTA. When the MC-1 tumour
cell is grown in tissue culture, examination
of a concentrate of the supernatant by
radioimmunoassay shows that there is
release of antigen into the media.
The results indicate that for the
MC-1 tumour detectable levels of cir-
culating TSTA are not reached with
normal metabolic cell surface turnover in
immunosuppressed rats. It would appear
that a local immune reaction is necessary
before detectable quantities of soluble
TSTA of less than 100,000 daltons are
released from the tumour into the systemic
circulation.
The thoracic ducts of rats were can-
nulated to allow daily sampling of
lymph from rats with MC-1 tumours
growing intramuscularly in the hind
limb. Lymph was obtained one day
before as a control and 1 through 10 days
after inoculation of 2 x 106 MC-1 sarcoma
cells. Soluble TSTA was detectable in
the lymph at 24 and 48 hours post-
inoculation, with 25 and 50% inhibition
of binding obtained. TSTA is bound
and phagocytosed by the draining regional
nodes and an immune reaction is stimu-
lated. Presumably because progressive
amounts of antigen are sequestered in
the nodes with time, TSTA was not
detectable in the lymph from 3 to 10
days after tumour inoculation.
DISCUSSION
The development of a radioimmuno-
assay for CEA by Thomson et al. (1969)
and x-foetoprotein (Ruoslahati and Sep-
pala, 1972) has allowed new facets of
human tumour immunology to be studied.
Similarly, the technique described here
for isolating and purifying tumour specific
antigenic determinants of chemically in-
duced tumours may offer the prospects of
chemically defining these determinants
and should facilitate the studY of their
role in the host-tumour relationship.
In addition, this method should be
applicable to the isolation and purification
of water-soluble human tumour antigens
(GCutterman et al., 1972) capable of
evoking a specific humoral immune re-
sponse (Bias et al., 1972; Lewis et al.,
1969).
Since the solubilized TSTA retains its
antigenicity, as determined by its ability
to neutralize MC-1 tumour immune
serum in the membrane immunofluo-
rescence assay, the technique of affinity
chromatography was chosen in order to
achieve selective isolation and purification
of the MC-1 tumour specific antigenic
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moiety. Sepharose - antibody columns,
unlike conventional techniques, are not
dependent on unique physiochemical cha-
racteristics of the protein. They utilize
immunoreactivity as the basis for separa-
tion and hence are particularly useful
in conjunction with radioimmunoassay.
Analysis by PAGE ofthe material isolated
by affinity chromatography revealed a
homogeneous component. This was not
due to nonspecific interaction with the
column matrix since other tumours (MC-3
and MC-11) did not yield a similar com-
ponent. Futhermore, the 1251 labelled
TSTA was specifically bound by MC-1
tumour immune y-globulin and the peak
of activity on PAGE was eliminated
whereas tumour immune sera from un-
related tumours did not alter the peak of
activity.
By the initial isolation procedure of
column chromatography, the MC-1 TSTA
had a molecular weight estimated to
be 40-50,000 (Thomson and Alexander,
1973a). The MC-1 TSTA moiety purified
by affinity chromatography has been
examined by dodecyl S04 gel electro-
phoresis (Weber and Osborn, 1969) and
by this method it has an apparent
molecular weight of 44,000 ± 2000. The
intact MC-1 TSTA moiety consists of
peptide fragments linked by disulphide
bonds since reduction with 2-mercapto-
ethanol yielded lower molecular weight
fragments (unpublished observations).
The molecular weight estimate of
44,000 for the MC-1 TSTA antigen is
close to that which has been reported
previously for the intact papain solubilized
HL-A and H-2 antigens (Sanderson,
Welsh and Cresswell, 1971; Nathenson,
Schwartz and Cullen, 1972). It is also
similar to the molecular weight of 43,000
which has recently been reported for
the detergent solubilized HL-A antigens
(Springer and Strominger, 1973). With
the similar H-2 antigenic system of mouse
detergent solubilized material has also
yielded molecular weights of about 43,000
(Nathenson et al., 1972). Thus, if any
fragment of the MC-1 TSTA antigen is
left behind in the membrane on solubiliza-
tion with papain this is likely to be
relatively small.
A common tumour associated antigen
was also isolated by affinity chromato-
graphy. On gel filtration its molecular
weight was estimated as approximately
50-70,000 daltons and dodecyl S04 gel
electrophoresis (unpublished observations)
has shown a single band common to all
tumours studied with a molecular weight
of approximately 27,000 1 4000, indicat-
ing that the common tumour antigen
probably exists as a dimer.
On the membranes of chemically
induced tumours of rats and in early
embryos a common tumour associated
antigen was previously detected by mem-
brane immunofluorescence with syngeneic
tumour immune serum and it was termed
" OEAI" (Thomson and Alexander,
I 973a). Studies have yet to be com-
pleted to determine if the common
tumour associated antigen isolated by
affinity chromatography and the OEA1
detected by membrane immunofluores-
cence are identical. Nevertheless, these
studies indicate that the TSTA, unique
for each chemically induced tumour, and
the common tumour associated antigen
are on separate membrane moieties.
Macromolecules normally associated
with the cell surface have been found in
a soluble form in the circulation. This
was clearly demonstrated in man in the
case of the carcinoembryonic antigen
(CEA) of colon (Thomson et al., 1969)
and the normal HL-A antigens (van
Rood, van Leuven and van Santen,
1970). In earlier studies it was found
that antibodies directed to the TSTA of
chemically induced sarcomata could not
be found in the serum of tumour bearing
rats, whereas after removal of tumour by
amputation of the leg, anti-TSTA anti-
bodies could be detected in the serum by
membrane immunofluorescence and by
mixed haemabsorption (Thomson et al.,
1973c). The most simple explanation,
that the antibody was absorbed in vivo
by the tumour, was shown not to be an
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important factor by measuring specific
antibody in the thoracic duct lymph to
the TSTA of sarcomata growing in the
leg. Here, it was shown that specific
antibody was low and rose sharply after
excision of the tuimour (Thomson et al.,
1973c). Consequently, we hypothesized
that in the presence of a growing tumour
soluble antigen escapes the tumour maAs
and complexes with specific antibody to
yield excess free soluble antigen and
immune complexes (see also Currie and
Basham, 1972; Currie and Gage, 1973).
Two different types of experiments
provided direct support for this hypothesis
and confirmed that in the circulation
of tumour bearers there were excess free
antigen anid immune complexes which
mask the demonstration of specific anti-
body by in vitro assays (Thomson et
al., 1973b). In syngeneic rats bearing
transplanted chemically-indutced hepato-
mata, Baldwin, Bowen and Price (I 973b)
have recently obtained similar results.
Our data draw attention to the soluble
antigens that escape the tumour mass
and become available to interact systemic-
ally with elements of the lymphoreticular
system. By radioimmunoassay, it was
shown that tumour transplantation is
associated with a persisting release of
soluble antigen into the circulation. This
antigenic burden is present continuously
an(l perpetually renewed as long as the
tumour mass exists. Soluble tumour
antigen becomes undetectable in the
circulation 48 hours after complete exci-
sion of the tumour. The factors involved
in the rate of elimination of soluble
antigen and immune complexes from the
circulation are numerous (Alpers, Steward
and Soothill, 1972) and may be expected
to vary in different animals and under
different circumstances.
None the less, after excision of the
tumour there is a close correlation between
the time of disappearance of circulating
tumour antigen, as demonstrated by
radioimmunoassay, andl the time of disap-
pearance of " blocking ", as demonstrated
by the in vitro cell mediated cytotoxicity
assay (Hellstrom, Hellstrom and Sjdgren,
1970; Baldwin, Embleton and Robbins,
1973a). Also, limited clinical data show
that blocking activity is seen primarily in
patients with growing tumour and is
frequently not found in patients who are
symptom-free(Hellstrometal., 1971;Currie,
1973). Further, other investigators have
shown that soluble histocompatibility anti-
gens, or tumour specific antigens in con-
centrations in excess of that required for
optimal stimulation, are capable ofspecific
abrogation of sensitized lymphocyte activ-
ity against target cells fn vitro (Brawn,
1971; Baldwin,EnmbletonandPrice, 1973c).
Sjogren et al. (1971) have postulated that
TSTA complexed with specific antibody
may constitute the " blocking " material
described by Hellstr6m et al. (1971) in
the serum of cancer patients. As already
indicated, specific antibody is produced
during tumour growth (Thomson et al.,
1973c) and this antibody complexes with
soluble circulating antigen (Thomson et
al., 1973b). Moreover, no evidence was
obtained to indicate that tumour cells in
situ are coated with significant quantities
of antibody (Thomson et al., 1973c).
With excision of the tumour, in spite of
the fact that the specific antibody levels
increase, the animals are now capable of
rejecting transplanted cells. Thus the
difference in the tumour bearing and
immune animal is not anti-TSTA anti-
body but the presence of circulating
tumour antigen either free or complexed
with specific antibody.
It seems probable, therefore, that the
"blocking " effect represents an in vitro
manifestation of a state of free soluble
antigenic moieties. Our results suggest
that the in vitro assay of " blocking "
is interpreted most simply as a measure
of circulating soluble tumour antigen.
The studies suggest that there are
3 mechanisms by which soluble TSTA is
released from the membrane of tumour
cells into the circulation: (1) spontaneous
release through metabolic turnover of
the cell surface; (2) during the course of
tumour necrosis; (3) as a by-product of an
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immune reaction bothcellularandhumoral.
Circulating soluble TSTA in the size
range of 10,000-100,000 daltons was
detected infrequently if the rats into
which the tumour has been implanted
were immunosuppressed by whole body
irradiation. It seems most likely, there-
fore, that an immune reaction, by attack-
ing and damaging the tumour cells,
enhances the release of excess free TSTA
systemically.
Prehn (1972) has postulated that the
effect of immunity on target cells might
be biphasic, that is, a mild reaction
stimulates tumour growth although a
strong one is cytotoxic. It may be
further hypothesized that in the early
evolution of tumours, when the immune
response is incipient and therefore weak,
direct lymphocyte and target cell inter-
action stimulates the tumour cell and
intensifies the release of soluble tumour
antigen. Acting locally, the soluble tu-
mour antigen " inhibits " efficient lympho-
cyte cytotoxicity and enhancement of
nascent tumour occurs. As the intensity
of the immune response builds up and the
lymphocytes become capable of a cyto-
toxic tumour effect, a larger mass of
tumour presents itself to the host as a
result of the previous stimulation of
tumour growth. While a more cytotoxic
tumour effect may occur, this again
releases soluble cell surface antigen and
produces feedback " inhibition " oflymph-
ocyte " killer " function. The tumour
mass progressively increases in size and
at some critical stage there is a transition
from local antigen excess to systemic
antigen excess which overwhelms the
host's immune response.
The phenomenon of feedback inhibi-
tion ofsoluble tumour antigen on lympho-
cytic " killer " function may explain why
in most instances the tumour develops,
metastasizes and finally kills the host
instead of encountering resistance and
being rejected eventually by an immune
reaction of the host.
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